Vanessa Research (VR) – a Hamden Connecticut-based biomedical company discovering, developing, and commercializing innovative products in areas of unmet medical needs – announced the appointment of Stephen Childs as Corporate Controller effective March 23, 2020. Childs will be a key member of the expanding company’s corporate financial team. With extensive experience in financial reporting and analysis, financial systems management, and product costing, Steven is expected to drive the international success of VR’s brand portfolio.
Childs is a graduate of Quinnipiac University and holds a graduate certificate in Accounting from the University of New Haven. He most recently served as VP – CFO for Ivy Biomedical Systems LLC. He has prior experience as financial controller in other companies including a 15-year tenure at Bigelow Tea Co. of Fairfield CT, where he served for five years as Assistant Controller.
Commenting on Steve’s new appointment, Don Janezic, CFO of VR stated: “Having worked with Steve Childs for 15 year at Bigelow Tea gives me keen insight into his unique abilities and excellent perspective on the role of Controller for Vanessa Research Holdings. He has demonstrated the ability to understand all phases of operations, sales and marketing, and the administration of a company like VR. Steve will be an excellent addition to our senior managers and VR will greatly benefit from his vast experience.”
Childs indicated that he is “excited to be offered this wonderful opportunity at Vanessa Research.” Equally, the Vanessa Research organization is very pleased to add the unique and proven skills and talent that Childs will provide in the company’s endeavor to fulfill its mission to ‘give hope where none existed’ – our promise to the world.
About Vanessa Research
Vanessa Research (VR) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets that are often overlooked. VR’s continually expanding pipeline of innovative pharmaceuticals, medical devices, and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare, lethal microvillus inclusion disease.
VR is based in New Haven, Connecticut, with offices in Budapest, Hungary; Munich, Germany; and Navarre, Spain.